Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARBOR study of elenestinib for indolent systemic mastocytosis
NL-OMON59974Phase 3Recruiting
- Sponsor
- Blueprint Medicines
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elenestinib in indolent systemic mastocytosis (ISM) and systemic mastocytosis (SM) (8 arms), sponsored by Blueprint Medicines. Primary endpoints: Safety and tolerability, Pharmacokinetics and pharmacodynamics and 1 more. Started May 2022; status: recruiting.
02
Drugs
elenestinib
03
Conditions
indolent systemic mastocytosis (ISM)systemic mastocytosis (SM)
Beyond the preview
Go deeper on NL-OMON59974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59974.